1.81
3.72%
-0.07
iBio Inc stock is currently priced at $1.81, with a 24-hour trading volume of 109.78K.
It has seen a -3.72% decreased in the last 24 hours and a -7.18% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.88 pivot point. If it approaches the $1.79 support level, significant changes may occur.
Previous Close:
$1.88
Open:
$1.9
24h Volume:
109.78K
Market Cap:
$15.59M
Revenue:
$2.05M
Net Income/Loss:
$-27.28M
P/E Ratio:
-0.3142
EPS:
-5.76
Net Cash Flow:
$-18.89M
1W Performance:
-3.72%
1M Performance:
-7.18%
6M Performance:
+576.13%
1Y Performance:
+94.62%
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
iBio Inc Stock (IBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
MarketWatch
IBIO Stock Earnings: iBio Reported Results for Q3 2024 - InvestorPlace
InvestorPlace
iBio Inc. stock falls Monday, underperforms market - MarketWatch
MarketWatch
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch
MarketWatch
iBio Inc Stock (IBIO) Financials Data
iBio Inc (IBIO) Revenue 2024
IBIO reported a revenue (TTM) of $2.04 million for the quarter ending September 30, 2021.
iBio Inc (IBIO) Net Income 2024
IBIO net income (TTM) was -$27.28 million for the quarter ending December 31, 2023, a +66.41% increase year-over-year.
iBio Inc (IBIO) Cash Flow 2024
IBIO recorded a free cash flow (TTM) of -$18.89 million for the quarter ending December 31, 2023, a +62.21% increase year-over-year.
iBio Inc (IBIO) Earnings per Share 2024
IBIO earnings per share (TTM) was -$15.02 for the quarter ending December 31, 2023, a +91.52% growth year-over-year.
About iBio Inc
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Cap:
|
Volume (24h):